{"id":"NCT02356588","sponsor":"Talphera, Inc","briefTitle":"A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02","primaryCompletion":"2015-06","completion":"2015-08","firstPosted":"2015-02-05","resultsPosted":"2017-02-13","lastUpdate":"2017-02-13"},"enrollment":161,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Post-Operative Pain"],"interventions":[{"type":"DRUG","name":"Sufentanil Tablet 30 mcg","otherNames":["ST 30 mcg"]},{"type":"DRUG","name":"Placebo Tablet","otherNames":["PT"]}],"arms":[{"label":"Sufentanil Tablet 30 mcg","type":"EXPERIMENTAL"},{"label":"Placebo Tablet","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and safety of the sublingual Sufentanil Tablet (ST) 30 mcg to the sublingual Placebo Tablet (PT) for the short-term management of moderate-to-severe acute post-operative pain in patients after abdominal surgery.","primaryOutcome":{"measure":"Time-weighted Summed Pain Intensity Difference (SPID) Over the 12-hour Study Period (SPID12).","timeFrame":"12 hours","effectByArm":[{"arm":"Sufentanil Tablet 30 mcg","deltaMin":25.84,"sd":1.71},{"arm":"Placebo Tablet","deltaMin":13.14,"sd":2.35}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":["Nausea","Headache","Dizziness","Hypotension","Vomiting"]}}